GH Research PLC will update the FDA on GH001's IND status and Phase 3 program for treatment-resistant depression on January 5, 2026.
Quiver AI Summary
GH Research PLC, a biopharmaceutical company focused on innovative treatments for depression, announced it will update investors regarding its Investigational New Drug Application for GH001 and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on January 5, 2026. GH001, their lead candidate, utilizes a proprietary inhalation method to deliver mebufotenin, showing promising results in the Phase 2b trial with a significant reduction in depressive symptoms compared to placebo. The company aims to develop transformative therapies for patients suffering from TRD.
Potential Positives
- GH Research PLC is set to provide a significant update regarding its Investigational New Drug Application (IND) for GH001, which may indicate upcoming progress in regulatory approval.
- The company reported positive results from its Phase 2b trial for GH001, indicating strong clinical activity in treating treatment-resistant depression (TRD) with a statistically significant reduction in MADRS scores.
- GH001's unique inhalation approach and its focus on transforming care for TRD positions GH Research PLC as a potentially innovative player in the biopharmaceutical market.
Potential Negatives
- The press release does not provide specific details or timelines regarding the status of the Investigational New Drug Application (IND), which may raise concerns about potential delays or uncertainties in getting regulatory approval for GH001.
- While the company reports positive results from the Phase 2b trial, no information is provided about potential risks or adverse effects associated with GH001, which could lead to skepticism among investors and stakeholders.
FAQ
What is GH Research PLC focused on?
GH Research PLC is dedicated to developing a transformative treatment for depression, especially in treatment-resistant cases.
What is GH001?
GH001 is GH Research PLC's lead product candidate, a mebufotenin therapy administered via a proprietary inhalation method.
When will GH Research provide an update on its IND application?
GH Research will provide an update on its IND application for GH001 on January 5, 2026, at 7:00 a.m. EST.
What were the results of the Phase 2b trial for GH001?
The Phase 2b trial showed a -15.5 point reduction in MADRS score from baseline on Day 8, indicating significant clinical activity.
How can investors contact GH Research PLC?
Investors can contact GH Research PLC through Julie Ryan at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GHRS Hedge Fund Activity
We have seen 31 institutional investors add shares of $GHRS stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK removed 1,967,293 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $28,132,289
- LYNX1 CAPITAL MANAGEMENT LP added 1,854,238 shares (+27.5%) to their portfolio in Q3 2025, for an estimated $26,515,603
- DEEP TRACK CAPITAL, LP removed 750,000 shares (-37.5%) from their portfolio in Q3 2025, for an estimated $10,725,000
- MILLENNIUM MANAGEMENT LLC added 659,957 shares (+324.1%) to their portfolio in Q3 2025, for an estimated $9,437,385
- STEMPOINT CAPITAL LP added 444,449 shares (+440.8%) to their portfolio in Q3 2025, for an estimated $6,355,620
- MORGAN STANLEY removed 276,760 shares (-98.5%) from their portfolio in Q3 2025, for an estimated $3,957,668
- FMR LLC added 234,900 shares (+4.6%) to their portfolio in Q3 2025, for an estimated $3,359,070
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$GHRS Analyst Ratings
Wall Street analysts have issued reports on $GHRS in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 11/10/2025
- Needham issued a "Buy" rating on 10/13/2025
To track analyst ratings and price targets for $GHRS, check out Quiver Quantitative's $GHRS forecast page.
$GHRS Price Targets
Multiple analysts have issued price targets for $GHRS recently. We have seen 2 analysts offer price targets for $GHRS in the last 6 months, with a median target of $27.0.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $35.0 on 11/10/2025
- Ami Fadia from Needham set a target price of $19.0 on 10/13/2025
Full Release
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported that it will provide an update on the status of its Investigational New Drug Application (IND) for GH001 with the U.S. Food and Drug Administration (FDA) and its global pivotal Phase 3 program in treatment-resistant depression (TRD) on Monday, January 5, 2026, at 7.00 a.m. EST.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC's initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.
About GH001
Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our Phase 2b GH001-TRD-201 trial, where the primary endpoint was met with a MADRS reduction from baseline of -15.5 points compared with placebo on Day 8 (p<0.0001), we believe that GH001 has the potential to change the way TRD is treated today.
Investor
Relations:
Julie Ryan
GH Research PLC
[email protected]
